Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.62 |
| ▸ | RXRB | P28702 | 18/20 | 0.62 |
| ▸ | RXRG | P48443 | 12/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | C5 | P01031 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700661 | 0.87 | RXRA (0.49) | RXRARXRBRXRGNR4A2KDM4E | |
| SCHEMBL2293918 | 0.84 | KDM4E (0.51) | RXRARXRBRXRGNR4A2KDM4E | |
| SCHEMBL2293345 | 0.81 | RXRA (0.41) | RXRARXRBRXRGNR4A2KDM4E | |
| SCHEMBL2296872 | 0.80 | RXRA (0.60) | RXRARXRBRXRGNR4A2KDM4E | |
| SCHEMBL6407346 | 0.77 | NR4A2 (0.39) | RXRARXRBRXRGNR4A2KDM4E | |
| SCHEMBL2292267 | 0.77 | ELANE (0.37) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8191237 | 0.76 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL3849972 | 0.76 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL3286 | 0.76 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| SCHEMBL13652909 | 0.74 | RXRA (0.70) | RXRARXRBRXRGNR4A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684766-B1 | USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-06-27 | — | — | EP | claimed |
| US-7232815-B2 | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | GLAXOSMITHKLINE (HR) | 2007-06-19 | — | — | US | claimed |
| US-20070111990-A1 | 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | claimed |
| EP-1492797-B1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | claimed |
| US-20050148576-A1 | 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | claimed |
| US-20050130956-A1 | 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20110200618-A1 | ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-18 | — | — | US | disclosed |
| WO-2009103072-A2 | ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-1684766-B1 | USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-06-27 | — | — | EP | disclosed |
| US-7232815-B2 | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | GLAXOSMITHKLINE (HR) | 2007-06-19 | — | — | US | disclosed |
| US-20070111990-A1 | 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2007-05-17 | — | — | US | disclosed |
| EP-1492797-B1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2006-03-15 | — | — | EP | disclosed |
| US-20050148576-A1 | 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-07-07 | — | — | US | disclosed |
| EP-1492797-A1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084964-A1 | 1-OXA-3-AZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PRODUCTION THEREOF | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148576-A1 | 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | TNF, IL1A, IL1B | RXRA 2092/4885RXRB 2214/4885RXRG 2662/4885 |
| US-20050130956-A1 | 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof | TNF, IL1A, IL1B | RXRA 1888/4885RXRB 2025/4885RXRG 2469/4885 |
| US-20070111990-A1 | 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | AZI2, DBH, BCHE | RXRA 2049/4885RXRB 2018/4885RXRG 2510/4885 |
| US-20110200618-A1 | ERBB4 INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ERBB4, ERBB3, ERBB2 | RXRA 2231/4885RXRB 1880/4885RXRG 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.